Finance

Beta
Lists
TVRD:NASDAQ
Tvardi Therapeutics Inc
$3.80
-24.00%
(-1.20) 1D
$4.11
+8.16% (+0.31)
After hours
Closed: Jul 9, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TVRD...
Open
$4.33
High
$5.05
Low
$3.77
Mkt. cap
22.10M
Avg. vol.
3.95M
Volume
7.49M
52-wk high
$43.65
52-wk low
$1.50
EPS
-$1.60
Beta
0.39
Shares outstanding
9.38M
No. of employees
12
Open
$4.33
High
$5.05
Low
$3.77
Mkt. cap
22.10M
Avg. vol.
3.95M
Volume
7.49M
52-wk high
$43.65
52-wk low
$1.50
EPS
-$1.60
Beta
0.39
Shares outstanding
9.38M
No. of employees
12
News stories
From sources across the web
About Tvardi Therapeutics Inc
CEO-
Employees12
Founded2017
HeadquartersSugar Land, Texas, United States
SectorPharmaceutical industry
Websitetvarditherapeutics.com
Analyst ratings
Based on 8 analysts giving stock ratings to TVRD in the past 3 months
Buy
Buy
6
Hold
1
Sell
1
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for TVRD in the last 3 months.
Highest
Current $3.80
$15.00 (+294.74%)
Average
$10.29 (+170.79%)
Lowest
$3.00 (-21.05%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yasmeen Rahimi
Piper Sandler
Buy
Upgraded
$13.00
+242.1%
07/08/2026
Julian Harrison
BTIG
Buy
Maintained
$15.00
+294.7%
07/07/2026
Ryan Deschner
Raymond James
Buy
Upgraded
$10.00
+163.2%
07/08/2026
Etzer Darout
Barclays
Sell
Maintained
$3.00
-21.1%
07/08/2026
Sara Nik
H.C. Wainwright
Buy
Maintained
$9.00
+136.8%
07/07/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$12.00
+215.8%
05/12/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
$10.00
+163.2%
05/11/2026
Unknown Analyst
Cantor Fitzgerald
Hold
Maintained
-
-
05/11/2026
Jay Olson
Oppenheimer
Buy
Reiterated
$10.00
+163.2%
04/02/2026
Steven Seedhouse
Cantor Fitzgerald
Hold
Maintained
-
-
04/01/2026
Christopher Liu
Lucid Capital
Buy
Upgraded
$6.00
+57.9%
02/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
5.81M
3.60M
5.49M
4.91M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.06M
2.34M
2.10M
2.14M
Operating expense
8.87M
5.94M
7.59M
7.05M
Total operating expenses
8.87M
5.94M
7.59M
7.05M
Operating income
-8.87M
-5.94M
-7.59M
-7.05M
Other non operating income
12.66M
-
-
-
EBT including unusual items
4.17M
-5.53M
-7.28M
-6.80M
EBT excluding unusual items
4.17M
-5.53M
-7.28M
-6.80M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
4.17M
-5.53M
-7.28M
-6.80M
Net profit margin
-
-
-
-
Earnings per share
0.51
-0.59
-0.78
-0.73
Interest and investment income
377.00K
411.00K
312.00K
247.00K
Interest expense
-
-
-
-
Net interest expenses
377.00K
411.00K
312.00K
247.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-8.85M
-5.91M
-7.56M
-7.03M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer